U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07513285) titled 'ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection' on March 24.
Brief Summary: Single-arm trial to evaluate the safety and efficacy of ACX-362E [ibezapolstat] in patients with recurrent C. difficile infection (CDI).
Study Start Date: Aug. 19, 2026
Study Type: INTERVENTIONAL
Condition:
Clostridium Difficile Infection Recurrence
Intervention:
DRUG: Ibezapolstat
Ibezapolstat 450 mg po Q12H x14 days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Acurx Pharmaceuticals Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....